financetom
Business
financetom
/
Business
/
Outlet mall firm Tanger posts rise in Q2 net income, raises 2025 guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Outlet mall firm Tanger posts rise in Q2 net income, raises 2025 guidance
Aug 4, 2025 2:00 PM

Overview

* Tanger Q2 net income rises to $0.26 per share, up from $0.22 year ago

* FFO per share increases to $0.58, reflecting strong leasing activity

* The owner and operator of outlet and open-air retail shopping destinations raises full-year 2025 guidance

Outlook

* Tanger raises full-year 2025 net income guidance to $0.93-$1.00 per share

* Company increases full-year 2025 FFO guidance to $2.24-$2.31 per share

* Tanger expects Same Center NOI growth of 2.5%-4.0% for 2025

* Company cites strong leasing and marketing strategies for raised guidance

Result Drivers

* LEASING STRATEGIES - Robust leasing activity with positive rent spreads driven by addition of in-demand retailers and entertainment options

* MARKETING INITIATIVES - Enhanced marketing campaigns like Tanger Deal Days and Summer of Savings increased shopper engagement and traffic

* OCCUPANCY IMPROVEMENT - Occupancy rose to 96.6% by end of Q2, reflecting successful tenant remerchandising and leasing efforts

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $133.44

Rental mln

Revenue

Q2 Net $31.33

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the commercial reits peer group is "buy"

* Wall Street's median 12-month price target for Tanger Inc ( SKT ) is $34.00, about 13.2% above its August 1 closing price of $29.52

* The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Essential Properties Realty Trust Keeps Quarterly Dividend at $0.295 a Share, Payable April 11 to Holders of Record on March 31
--Essential Properties Realty Trust Keeps Quarterly Dividend at $0.295 a Share, Payable April 11 to Holders of Record on March 31
Mar 10, 2025
10:25 AM EDT, 03/10/2025 (MT Newswires) -- Price: 32.44, Change: +0.15, Percent Change: +0.46 ...
Summit Midstream Acquires Moonrise Midstream for $90 Million
Summit Midstream Acquires Moonrise Midstream for $90 Million
Mar 10, 2025
10:23 AM EDT, 03/10/2025 (MT Newswires) -- Summit Midstream ( SMC ) said Monday that its Summit Midstream Holdings unit acquired Moonrise Midstream from Fundare Resources for $90 million in a cash-and-stock deal. The company said it paid $70 million in cash upfront and $20 million in equity representing about 500,000 shares of Summit Midstream ( SMC ). The cash...
More chance of Elvis speaking than energy transition plans succeeding, Aramco CEO says
More chance of Elvis speaking than energy transition plans succeeding, Aramco CEO says
Mar 10, 2025
By Arathy Somasekhar and Maha El Dahan HOUSTON (Reuters) - Policymakers and energy executives need to rethink energy transition plans and stop doubling down on elements of the transition that have failed, the CEO of state oil giant Saudi Aramco said on Monday, stressing the need for investment in fossil fuels to meet global demand. The comments from the head...
Agilent's Cancer Diagnostic Kit Receives EU Approval for Two New Indications
Agilent's Cancer Diagnostic Kit Receives EU Approval for Two New Indications
Mar 10, 2025
10:20 AM EDT, 03/10/2025 (MT Newswires) -- Agilent Technologies ( A ) said Monday that its PD-L1 IHC 28-8 pharmDx kit was approved for two new companion diagnostic indications in the European Union. The kit is now approved as a companion diagnostic test for malignant melanoma and non-small cell lung cancer, Agilent ( A ) said. The new approvals bring...
Copyright 2023-2026 - www.financetom.com All Rights Reserved